Candidiasis mucocutánea: espectro clínico

-A A +A
Artículo de revisión
Rev Asoc Colomb Dermatol. 2011;19: 239-244.

Candidiasis mucocutánea: espectro clínico

Clinical spectrum of mucocutaneous candidiasis
Autor(es): 
Claudia Patricia Palacios
claupala@yahoo.com
Médica, residente de Dermatología, Universidad Pontificia Bolivariana, Medellín, Colombia
Luz Marina Gómez
Médica, dermatóloga; profesora titular y jefe del Servicio de Dermatología, Universidad Pontificia Bolivariana, Medellín, Colombia
Nora Cardona
Médica, M.Sc., Universidad CES, Instituto Colombiano de Medicina Tropical, Medellín, Colombia
Resumen: 

La candidiasis mucocutánea es una infección superficial común en nuestro medio, con múltiples factores de riesgo para su desarrollo. En las últimas décadas se ha incrementado su presentación, ya que tiene gran asociación con el VIH-sida, aunque también se presenta en personas inmunocompetentes. El agente etiológico más común es Candida albicans. La candidiasis superficial puede comprometer piel, mucosas y uñas, y existe la forma mucocutánea crónica que se asocia a enfermedades autoinmunitarias. Se hace una revisión de las principales formas de candidiasis mucocutánea y su implicación clínica en la población general.

Palabras clave: 
Candida, candidiasis cutánea, Intertrigo, candidiasis oral, balanitis candidiásica, vulvovaginitis.

Summary: 

Mucocutaneous candidiasis is a superficial infection very common in our environment, with multiple risk factors for its development. In recent decades its presentation has increased since it is strongly associated with HIV/AIDS, but it may also present in immunocompetent patients. The most common etiological agent is Candida albicans. Superficial candidiasis may involve the skin, mucous membranes, and the nail and there is a chronic mucocutaneous form associated with other autoimmune diseases. We review the main forms of mucocutaneous candidiasis and its clinical implication in the general population.

Key words: 
Candida, cutaneous candidiasis, intertrigo, oral candidiasis, candidal balanitis, vulvovaginitis.
PDF del articulo

Referencias

1. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503-35.

2. López R. Candidiosis, a new challenge. Clin Dermatol. 2010;28:178-84.

3. Anaisse EJ, McGiniss MR, Pfaller MA. Clinical mycology. New York: Churchill Livingstone; 2003. p. 608-10.

4. Arango M, Castañeda E. Micosis humanas. Procedimientos diagnósticos. Exámenes directos. Medellín, Bogotá: Corporación para Investigaciones Biológicas-Instituto Nacional de Salud; 2003.

5. Sullivan DJ, Westerneng TJ, Haynes KA, Bennett DE, Coleman DC. Candida dubliniensis sp. nov.: Phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology. 1995;141:1507-2.

6. Janik P, Heffernan M. Yeast infections: Candidiasis and Tinea (Pytiriasis) Versicolor. In: Wolff K, Goldsmith L, Katz S, Leffell D, editors. Fitzpatrick’s Dermatology in general medicine. Chicago: McGraw-Hill; 2002. p. 1822-30.

7. Samaranayake LP. Nuevas perspectivas en la epidemiología y etiopatogénesis de la candidiasis oral. Gac Med Bilbao. 2001;98:15-6.

8. Cannon RD, Chaffin WL. Oral colonization by Candida albicans. Crit Rev Oral Biol Med. 1999;10:359-83.

9. Cannon RD, Holmes AR, Mason AB, Monk BC. Oral candida: Clearance, colonization, or candidiasis? I Dent Res. 1995;74:1152-61.

10. Farah CS, Ashman RB, Challacombe SJ. Oral candidiosis. Clin Dermatol. 2000;18:553-62.

11. Palmer GD, Robinson PG, Challacombe SJ, Birnbaum W, Croser D, Erridge PL, et al. Aetiological factors for oral manifestations of HIV. Oral Dis. 1996;2:193-7.

12. Samaranayake LP. Host factor and oral candidosis. In: Samaranayake LP, d MacFarlane TW, editors. Oral candidosis. London: 1990. p. 63-106.

13. Scully C, Epstein J, Porter S. Recognition of oral lesions of HIV infections. Candidosis. Br Dent J. 1990;169:295-6.

14. Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, et al. Vulvovaginal candidiasis: Epidemiologic,diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998;178:203-11.

15. Pirotta MV, Garland SM. Her choice: Dealing with lactobacilli, vaginitis, and antibiotics. Curr Infect Dis Rep. 2005;7:445-52.

16. Fidel PL. History and new insights into host defense against vaginal candidiasis. Trends Microbiol. 2004;12:220-7. 17. Sobel JD. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis. 1992;14:148-53.

18. Cardona N, Revankar S, Ortiz P, Cuervo C, Kirkpatrick WR, McAtee RK, et al. Proteinase detection, DNA typing and antimycotic susceptibility of Candida isolates from Colombian women with vulvovaginal candidiasis. Rev Iberoam Micol. 2002;19:89-94.

19. Sobel JD. Vulvovaginal candidosis. Lancet. 2007;369:1961-71.

20. Sobel JD. Vaginal infections. Medicine. 2010;38:286-90.

21. Sobel JD, Chaim W, Nagoppan V, Leaman D. Treatment of vaginitis caused by Candida glabrata: Use of topical boric acid and flucytosine. Am J Obstet Gynecol. 2003;189:1297-300.

22. Rodríguez A, García B. Mucocutaneous candidiasis: Clinical manifestations. Med Clín (Barc.). 2006;126(Suppl.1):20-4.

23. Jayatilake JA, Tilakaratne WM, Panagoda GJ. Candidal onychomycosis: A mini Review. Mycopathologia. 2009;168:165-73.

24. Gonzalez RE, Valdebrán MA, Guidos HE. Candidiasis mucocutánea crónica informe de caso. Arch Argent Pediatr. 2010;108:37-40.

25. De Moraes-Vasconcelos D, Orii NM, Romano CC, Iqueoka RY, Duarte AJ, et al. Characterization of the cellular immune function of patients with chronic mucocutaneous candidiasis. Clin Exp Immunol. 2001;123:247-53.

26. Lilic D, Gravenor I, Robson N, Lammas DA, Drysdale P, Calvert JE, et al. Deregulated production of protective cytokines in response to Candida albicans infection in patients with chronic mucocutaneous candidiasis. Infect Immun. 2003;71:5690-9.

27. van der Graaf CA, Netea MG, Drenth IP, Morsche RH, van der Meer JW, Kullberg BJ. Candida-specific interferongamma deficiency and toll-like receptor polymorphisms in patients with chronic mucocutaneous candidiasis. Neth J Med. 2003;61:365-9.

28. Venkatesan P, Perfect JR, Myers SA. Evaluation and management of fungal infections in immunocompromised patients. Dermatol Ther. 2005;18:44-57.

29. Hoepelman IM, Dupont B. Oral candidiasis: The clinical challenge of resistance and management. Int J Antimicrob Agents. 1996;6:155-9.

30. Trope BM, Lenzi ME. Infecção pelo HIV. In: Ramos-e-Silva M, Castro MCR, editors. Fundamentos de dermatología. Río de Janeiro: Atheneu; 2009. p. 1003-27.

31. Chen T, Cockerell C. Cutaneous manifestations of HIV infection and HIV-related disorders. In: Bolognia J, Jorizzo J, Rapini R, editors. Dermatology. Second edition. New York: Elsevier; 2008. p. 1165-81.

32. Conant MA. Fungal infections in immunocompromised individuals. Dermatol Clin. 1996;14:155-62.

33. Wright SW, Johnson RA. Human immunodeficiency virus in women: Mucocutaneous manifestations. Clin Dermatol. 1997;15:93-111.

34. Ruhnke M. Mucosal and systemic fungal infections in patients with AIDS: Prophylaxis and treatment. Drugs. 2004;64:1163-80.

35. Johnson RA. Dermatophyte infections in human immune deficiency virus (HIV) disease. J Am Acad Dermatol. 2000;43:135-S142.

36. Ramos-E-Silva M, Lima CM, Schechtman RC, Trope BM, Carneiro S. Superficial mycoses in immunodepressed patients (AIDS). Clin Dermatol. 2010;28:217–25.

37. Aly R, Berguer T. Common superficial fungal infections in patients with AIDS. Clin Infect Dis. 1996;22(Suppl.2):S128-32.

38. Nnoruka EN, Chukwuka JC, Anisuiba BN. Correlation of mucocutaneous manifestations of HIV/AIDS infection with CD4 counts and disease progression. Int J Dermatol. 2007;46(Suppl.2):14-8.

39. Sharma SK, Hadhiravan T. Management of the patient with HIV infection In: Rakel RE, Bope ET, editors. Conn’s Current Therapy 2008. Philadelphia: Saunders Elsevier; 2008. p. 47-61.

40. Clearinghouse EC. On oral problems related to HIV infection and WHO collaborating centre on oral manifestations of the immunodeficiency virus. Classification and diagnostic criteria for oral lesions in HIV infection. J Oral Pathol Med. 1993;22:289-91.

41. Arribas JR, Hernández-Albújar S, González-García JJ, Pena JM, González A, Canedo T, et al. Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. AIDS. 2000;14:979-85.

42. Hogan MT. Cutaneous infections associated with HIV/AIDS. Dermatol Clin. 2006;24:473-95.

43. Prose NS, Abson KG, Scher RK. Disorders of nails and hair associated with human immunodeficiency virus infection. Int J Dermatol. 1992;32:453-7.

44. Sullivan DJ, Westerneng TJ, Haynes KA, Bennett DE, Coleman DC. Candida dubliniensis sp.: Phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology. 1995;141:1507-21.

45. Alcoba-Flores J, Méndez-Álvarez S, Cano J, Guarro J, PérezRoth E, del Pilar Arévalo M. Phenotypic and molecular characterization of Candida nivariensis sp. Nov; a possible new opportunistic fungus. J Clin Microbiol. 2005;43:4107-11.

46. Samaranayake LP. Nuevas perspectivas en la epidemiología y etiopatogénesis de la candidiasis oral. Gac Med Bilbao. 2001;98:15-6.

47. Chen S, Sorrell T. Antifungal agents. Med J Austral. 2007;187:404-9.

48. Vázquez JA, Skiest DJ, Nieto L, Northland R, Sanne I, Gogate J. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis. 2006;42:1179-86.

49. Scully C, El-kabir M, Samaranayake LP. Candida and oral candidiosis: A review. Crit Rev Oral Biol Med. 1994;5:125-57.

50. Scott LJ, Simpson D. Voriconazole. A review of its use in the management of invasive fungal infection. Drugs. 2007;67:269-98.

51. Calle J, Cardona N. Micosis más prevalentes en pacientes con VIH/SIDA, correlación con el estado inmunológico del huésped. Rev Asoc Colomb Dermatol. 2009;17:211-20.

Cutaneous tuberculosis, a diagnostic challenge
Rev Asoc Colomb Dermatol. 2011;19: 249-251.
Clinical spectrum of mucocutaneous candidiasis
Rev Asoc Colomb Dermatol. 2011;19: 239-244.
Gout and its dermatological manifestations
Rev Asoc Colomb Dermatol. 2011;19: 231-236
Approach and management of hypertrophic scars and keloids
Rev Asoc Colomb Dermatol. 2011;19: 218-228
Epidemiologic characteristics of patients with cutaneous squamous cell carcinoma in Centro Dermatológico Federico Lleras Acosta, Bogotá, Colombia
Rev Asoc Colomb Dermatol. 2011;19: 212-217
Clinical-pathological correlation of skin biopsies, Dermatology Service. Complejo Hospitalario Dr. Arnulfo Arias Madrid, Panamá, October, 2006-October, 2008
Rev Asoc Colomb Dermatol. 2011;19: 205-211
Usefulness of nail plate sample in the diagnosis of onychomycosis
Rev Asoc Colomb Dermatol. 2011;19: 194-200
.
Rev Asoc Colomb Dermatol. 2011; 19: 192-193

PATROCINADORES PRINCIPALES

  • MEDIHEALTH
  • SESDERMA
  • MD FARMACIA MAGISTRAL
  • EPIDERMIQUE
  • ISDIN
  • GALDERMA